United States · FDA National Drug Code directory

human papillomavirus quadrivalent (types 6, 11, 16, and 18)

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
63552-212_2df92a73-f81c-646f-e063-6294a90a1c88
Product NDC
63552-212
Form
INJECTION, SUSPENSION
Composition / generic term
human papillomavirus quadrivalent (types 6, 11, 16, and 18)
Labeler
Patheon Manufacturing Services LLC
Marketing category
DRUG FOR FURTHER PROCESSING
Marketing start / end (source format)
20241223
Source listing expiry
20261231

Source-listed ingredients

  • HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN — 20 ug/.5mL
  • HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN — 40 ug/.5mL
  • HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN — 20 ug/.5mL
  • HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN — 40 ug/.5mL

These values do not establish equivalence or a dose recommendation.

Packages

  • 388 VIAL, SINGLE-DOSE in 1 TRAY (63552-212-00) / .5 mL in 1 VIAL, SINGLE-DOSE (63552-212-05) · 63552-212-00

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →